

# Quantum processing of cytidine derivatives and evaluating their *in silico* interactions with the COVID-19 main protease

Kun Harismah<sup>a</sup>, Narjes Hajali<sup>b</sup>, Mahmoud Mirzaei<sup>c,\*</sup> and Elham Salarrezaei<sup>d</sup>

<sup>a</sup>Department of Chemical Engineering, Faculty of Engineering, Universitas Muhammadiyah Surakarta, Surakarta, Indonesia

<sup>b</sup>Department of Chemistry, Faculty of Science, Central Tehran Branch, Islamic Azad University, Tehran, Iran

<sup>c</sup>Medical Image & Signal Processing Research Center, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>d</sup>Department of Biomaterials, Nanotechnology and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Abstract.** This work was performed by the importance of exploring possible medications for COVID-19 pandemic. In this regard, cytidine (Cyd) derivatives were investigated to reach a point to see their benefit of employing for the purpose. Each of halogenated models of Cyd including CydF, CydCl, CydBr, and CydI were investigated in addition to the original CydH model. Density functional theory (DFT) based quantum processing were performed to obtain stabilized structures in addition to evaluation of frontier molecular orbitals features. Next, molecular docking (MD) simulations were performed to reach a point of formations of interacting ligand-target complexes. Among the investigated models CydH and CydI were working better than other model for reaching the purpose of this work, in which the derived CydI model was indeed the ligand with the highest suitability for formation of ligand-target complexes. As a consequence, such ligands of original and halogenated Cyd models might work for inhibition of main protease (MPro) enzyme of COVID-19 based on the obtained meaningful vales for complex strengths in addition interacting with the amino acids of active site. More precisely, the CydI model could be proposed as promising ligand for showing the inhibitory effects towards the MPro target of COVID-19.

**Keywords:** Coronavirus, COVID-19, cytidine, enzyme inhibition, *In silico*

## 1. Introduction

Since the end of 2019, the world has been shocked and seriously affected by the appearance of coronavirus disease (COVID-19) [1–3]. After about two years, the problem has not been solved yet and so many people all around the world have been infected by this mysterious virus [4–6]. To this point, considerable efforts have been done to innovate pharmaceutical compounds for prevention or medication of infection by COVID-19; however, the results have not been certain yet and investigation are still under developments [7–9]. Moreover, several procedures were employed for detection of

\*Corresponding author: Mahmoud Mirzaei, Medical Image & Signal Processing Research Center, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: mdmirzaei@pharm.mui.ac.ir.


31 such COVID-19 in the infected people [10–12]. Among various medical protocols of vaccination or  
32 medication, several attempts have been devoted to find inhibitors for the main protease (MPro) enzyme  
33 of coronavirus preventing the infection development [13–15]. To this aim, available drugs have been  
34 extensively examined for inhibiting the enzyme activity in addition to developing new pharmaceutical  
35 compounds for achieving a possible solution for this serious problem [16–18]. By complexity of  
36 performing investigations on biological systems and the COVID-19 related studies, employing the *in*  
37 *silico* approach could help to provide insightful information for approaching to a brighter point about  
38 this really unknown disease [19–21]. The current work was performed to examine potency of cytidine  
39 for inhibiting the activity of MPro COVID-19 employing the computer-based *in silico* approach. In  
40 recent years, several computer-based tools have been developed to solve the problems in science and  
41 technology, especially those related to the living systems [22–24].

42 Cytidine (Cyd) is a nucleoside derivative of cytosine nucleobase, which showed several features in  
43 medical applications [25–27]. Indeed, considerable attempts have been devoted to explore medical  
44 functions of nucleobases derivatives in living systems after the pioneering characterization work of  
45 Watson and Crick [28–30]. To this point, Cyd has been seen as a pharmaceutical compound for  
46 enzymatic activity inhibitions by earlier works [31–33]. Hence, the hypothesis of MPro inhibition  
47 by Cyd was investigated in this work to show potency of this already known compound towards  
48 medication of COVID-19 patients. In addition to the original nucleobases, halogenated derivatives  
49 have been always important for showing specific functions, in which such halogenated derivatives of  
50 Cyd were also examined in this work to approach the purpose. As a consequence, molecular models  
51 of Cyd in the role of ligand, and molecular model of MPro in the role of target, were considered in  
52 this work for analyzing their corresponding features. To do this, quantum processing of ligands were  
53 done employing density functional theory (DFT) approach to obtain theoretically meaningful ligand  
54 compounds for participating in interactions with the MPro target. Accordingly, molecular docking  
55 (MD) simulations were performed to reach the interacting ligand-target complexes by evaluating the  
56 interaction strength in addition to identifying the surrounding amino acids around the centralized  
57 ligand. It is important to mention here that existence of hydrogen bond and van der Waals interactions  
58 could both help to formation of interacting ligand-target complexes [34]. Table 1 and Fig. 1 represent  
59 the ligands specifications and interacting features for the models to examine the hypothesis of MPro  
60 inhibition by assistance of the investigated Cyd derivatives. It is worth to mention that the result of  
61 current work could provide knowledge about existence of possible inhibitors for the medication of  
62 COVID-19 patients.

## 63 2. Materials and methods

64 Within this work, the original models of Cyd in addition to halogenated derivatives were considered  
65 as the ligands, in which their specifications were listed in Table 1. Earlier works indicated that the  
66 carbon atom number five of pyrimidine nucleobases is an important atomic site to be functionalized  
67 with other substances such as halogen atoms [35]. Accordingly, such benefit was employed in this  
68 work to functionalize cytosine counterpart of Cyd by each of F, Cl, Br, and I halogenated atoms. As a  
69 consequence, four derivatives were added to the original Cyd to provide ligands of this work including  
70 CydH, CydF, CydCl, CydBr, and CydI. Quantum processing were performed to optimize the molecular  
71 models of each of ligand structures employing DFT approach as implemented in the Gaussian program  
72 [36]. By doing this step, stabilized models with theoretically meaningful geometries were obtained  
73 for further investigating their own features in addition to their contribution to interaction with the  
74 MPro enzyme target of COVID-19. The 3D macromolecular model of MPro (6lu7) was obtained  
75 from the Protein Data Bank (PDB) [37] to be considered for the target model of interacting complex

Table 1  
Ligands specifications



Ligand	R	HOMO eV	LUMO eV	EG eV	H eV	S eV <sup>-1</sup>	DM Debye
CydH	H	-6.36	-0.99	5.37	2.68	0.37	4.88
CydF	F	-6.32	-1.21	5.11	2.56	0.39	3.99
CydCl	Cl	-6.42	-1.29	5.13	2.56	0.39	3.68
CydBr	Br	-6.38	-1.27	5.11	2.56	0.39	3.79
CydI	I	-6.28	-1.36	4.92	2.46	0.41	4.01

formations with each of Cyd ligands. The accurate MD simulations were performed by submitting each of provided ligand and target structures to the Swiss Dock web server [38] for evaluating interacting ligand-target complexes in a defined 70\*70\*70 grid box. As a consequence, required features were evaluated for describing each of ligand structures in addition to the obtained interacting ligand-target complexes. Returning to Table 1, frontier molecular orbital quantities were evaluated for the ligands including energy levels of the highest occupied and the lowest unoccupied molecular orbitals (HOMO and LUMO), energy differences of HOMO and LUMO levels in terms of energy gap (EG), chemical hardness and softness (H and S), and dipole moment (DM). Moreover, representations of HOMO-LUMO distribution patterns and electrostatic potential (ESP) surfaces of the ligands were visualized in Fig. 1 besides the evaluated interacting ligand-target complex systems. Values of  $\Delta G$  (kcal/mol) and RMSD implied for energetic strengths of interactions and conformational fluctuations of ligands from the start point up to the end point of MD simulations. As a consequence, required information were provided for discussing the hypothesis of employing Cyd ligands for inhibition of the MPro of COVID-19.

### 3. Results and discussion

The hypothesis of inhibition of MPro of COVID-19 by assistance of Cyd derivatives was examined in this work employing the *in silico* approach. To this aim, five models of Cyd derivatives were obtained by halogenation of the atomic site number five of main cytosine group to evaluate CydF, CydCl, CydBr, and CydI derivatives in addition the original CydH compound. As described in Table 1, the models were varied by the attached R group, in which each of F, Cl, Br, and I atoms were substituted instead of the H atom of original Cyd. As a consequence, the models structures were provided to be included in the DFT based quantum processing to approach to the minimized energy structures. Doing this step, five theoretically meaningful ligands were obtained for further analyzing their features besides examining their contributions to interactions with the MPro target. For analyzing the ligand structures, values of




Fig. 1. HOMO-LUMO distribution patterns and ESP surfaces of ligands and interacting ligand-target complexes.

100 HOMO and LUMO were evaluated to show their tendency of participating in electron transferring  
 101 processes. Indeed, such molecular orbitals features could reactivity of a molecule for contributing to  
 102 interactions with other substances [39]. HOMO implies for the highest occupied molecular orbital with  
 103 electrons, in which its occupation means that how a molecule could participate in electron donating

104 process. On the other hand, LUMO implies for the lowest unoccupied molecular orbital without  
105 electrons, in which its vacancy means that how a molecule could participate in electron accepting  
106 process. In this regard, their energy levels are important because of providing appropriate levels of  
107 electron transferring. Moreover, energy differences of HOMO and LUMO of a molecule in terms of  
108 energy gap (EG) imply for energy distances for internal electron transitions, as an important feature  
109 for electron conductivity processes. These points are important because of the detection role of an  
110 inhibitor for detecting the correct target prior to contributing to interactions with it, in which concepts  
111 of biosensors could be considered for such purpose. Therefore, analyzing such frontier molecular  
112 orbitals features could show insightful information about the characteristic properties of investigated  
113 Cyd derivatives.

114 As could be seen in Table 1, each of HOMO and LUMO levels detected effects of halogenation  
115 by changes of values among the models. With the exception of CydCl model, HOMO levels for  
116 all other halogenated models moved to higher level in comparison with the original CydH model.  
117 However, LUMO levels of all halogenated derivatives were moved to lower levels in comparison  
118 with the original CydH model. Among the models, the characteristic HOMO-LUMO achievements  
119 were obtained for CydI model with the highest HOMO level and the lowest LUMO level among all  
120 halogenated derivatives. Such characteristic structural feature could mean that another characteristic  
121 activity could be expected for such ligand model. Indeed, structure-activity relationship (SAR) is an  
122 important concept in the field of drug design for innovating structures with promising activity in living  
123 systems [40]. As a consequence, structural features could lead to desired activity for approaching the  
124 purposes of detection and medication in living systems. Comparing values of EG shows shorter energy  
125 distances for the halogenated Cyd derivatives in comparison with the original CydH model, in which  
126 that of CydI was placed at the shortest distance. Accordingly, evaluated values of chemical hardness  
127 and softness (H and S) from the obtained HOMO and LUMO levels could show lower hardness and  
128 higher softness for CydI model for contributing to reactions/interactions with other substances. Among  
129 the models, H and S of CydF, CydCl, and CydBr were almost close to those of CydH; however, CydI  
130 was indeed distinguished in the models. Lead optimization is another important concept in drug design  
131 meaning how to modify a known structure to find better features regarding the desired purposes [41],  
132 in which such concept was explored in the current work by modifying CydH model to reach a more  
133 efficient compound as could be seen by the obtained features of CydI model. By the changes of  
134 functionalized groups and total structural configurations, values of dipole moment (DM) could show  
135 such fluctuations for electric charge distributions of the models. Although an atomic substitution was  
136 done for the ligand models, but changes of DM were notable affirming the importance of knowing  
137 structural features and their corresponding electric properties to show evaluate appropriate models. As  
138 a consequence of performing quantum processing on Cyd ligands, halogenations brought new features  
139 for the models with promising roles for the obtained CydI model.

140 As could be seen in Fig. 1, the evaluated HOMO-LUMO distribution patterns and ESP surfaces by  
141 performing quantum processing and the evaluated interacting ligand-target complexes by performing  
142 MD simulations were visualized and represented. Within these results, it could be found that the  
143 shapes of HOMO-LUMO patterns were almost similar for CydH, CydF, CydCl, and CydBr models  
144 but different from the already distinguished CydI model. Moreover, careful comparison of the ESP  
145 surfaces could show that the occupied space of was increased by additional of halogen atoms, in  
146 which increasing the size of atomic radius of halogen atom led to expanding the model surface.  
147 Red, yellow, green, light blue, and blue colors of ESP surfaces imply for localizing negative, slightly  
148 negative, neutral, slightly positive, and positive charges at the surface. In this case, the models could  
149 be defined for participating in interactions with other substances. Returning again to values of HOMO-  
150 LUMO, those of CydI model were in characteristic mode with repeating such characteristic feature for  
151 distribution patterns. Indeed, different type of localization of HOMO-LUMO might be an advantage

of molecule for better contributing to the external interactions, in which such feature could be expected for the CydI model better than the other models. In this regard, the obtained interacting ligand-target complexes could show that such halogenation changed strength of obtained complexes. Based on the obtained  $\Delta G$  values, strengths of all complex models were meaningful in accordance with the obtained energies showing total advantage of investigating such Cyd derivatives for possible inhibition of the MPro of COVID-19. Moreover, each of CydH and CydI models showed even better features of interactions in comparisons with the other models. The surrounding amino acids of centralized ligand were all in the active site region of enzyme, in which various types of interactions were seen for ligand-target complexes. In addition to existence of conventional hydrogen bond (HB) interactions, non-HB interactions also play important roles for formations of biomolecular complexes as shown for the investigated models. Another impact of halogenation was seen by increasing RMSD for the ligand counterpart to reach the relaxed conformation towards the target. Indeed, such conformational changes could help each of ligand and target structures to fine the best positions of complex formations. As a consequence, performing halogenated mode of lead optimization for Cyd yielded CydI by distinguished features in single-standing mode and complex formation. Hence, this model could be proposed for further investigating regarding innovation of inhibitors for the MPro of COVID-19.

#### 4. Conclusion

DFT based quantum processing and MD simulations were performed to provide required results for analyzing Cyd models for the purpose of MPro inhibiting of COVID-19. In this regard, the results indicated that the stabilized models of halogenated Cyd could be achievable by performing DFT calculations and their frontier molecular orbital features could provide information about their characteristic features. To this point, quantities of HOMO-LUMO and corresponding distribution patterns all showed significant features for the models distinguishing CydI model for approaching the purpose. Chemical hardness and softness were more suitable for CydI model in comparison with other models, in which complex formation of this ligand structure was still at the most suitability. Analyzing HOMO-LUMO distribution patterns showed changes of such orbital localization for CydI model in comparison with the other models implying for the promising features of CydI model. As a concluding result of this work, lead optimization of Cyd model yielded a better model of CydI derivative with appropriate features to be considered for investigating MPro inhibitors of COVID-19.

#### Acknowledgments

The support of this work by the research council of Isfahan University of Medical Sciences under grant number 299126 is acknowledged.

#### References

- [1] T.P. Velavan and C.G. Meyer, The COVID-19 epidemic, *Tropical Medicine & International Health* **25** (2020), 278–80.
- [2] O.M. Ozkendir, M. Askar and N.E. Kocer, Influence of the epidemic COVID-19: an outlook on health, business and scientific studies, *Lab-in-Silico* **1** (2020), 26–30.
- [3] S. Arshizadeh, S.H. Gorgani, P. Taheri, M. Givgol, S. Shahrokhi and A. Abdalisousan, The impact of COVID-19 on oil supply in the short term, *Advanced Journal of Science and Engineering* **2** (2021), 120–35.
- [4] J.V. Lazarus, S.C. Ratzan, A. Palayew, L.O. Gostin, H.J. Larson, K. Rabin, S. Kimball and A. El-Mohandes, A global survey of potential acceptance of a COVID-19 vaccine, *Nature Medicine* **27** (2021), 225–8.
- [5] O. Vandenberg, D. Martiny, O. Rochas, A. van Belkum, Z. Kozlakidis, Considerations for diagnostic COVID-19 tests, *Nature Reviews Microbiology* **19** (2021), 171–83.
- [6] P. Brodin, Immune determinants of COVID-19 disease presentation and severity, *Nature Medicine* **27** (2021), 28–33.

- 195 [7] M.T. Rahman and S.Z. Idid, Can Zn be a critical element in COVID-19 treatment? *Biological Trace Element Research*  
196 **199** (2021), 550–8.
- 197 [8] H. Liu, J. Liu, S. Hou, T. Tao and J. Han, Perception consistency ultrasound image super-resolution via self-supervised  
198 CycleGAN, *Neural Computing and Applications*. 2021; in press.
- 199 [9] H.M. Dabbous, S. Abd-Elsalam, M.H. El-Sayed, A.F. Sherief, F.F. Ebeid, M.S. Abd El Ghafar, S. Soliman, M.  
200 Elbahnasawy, R. Badawi and M.A. Tageldin, Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized  
201 study, *Archives of Virology* **166** (202), 949–54.
- 202 [10] Y. Yang, J. Liu and X. Zhou, A CRISPR-based and post-amplification coupled SARS-CoV-2 detection with a portable  
203 evanescent wave biosensor, *Biosensors and Bioelectronics* **190** (2021), 113418.
- 204 [11] C. Xue, J. You, H. Zhang, S. Xiong, T. Yin, Q. Huang, Capacity of myofibrillar protein to adsorb characteristic fishy-  
205 odor compounds: Effects of concentration, temperature, ionic strength, pH and yeast glucan addition, *Food Chemistry*  
206 **363** (2021), 130304.
- 207 [12] X. Li, Z.Q. Dong, P. Yu, L.P. Wang, X.D. Niu, H. Yamaguchi and D.C. Li, Effect of self-assembly on fluorescence  
208 in magnetic multiphase flows and its application on the novel detection for COVID-19, *Physics of Fluids* **33** (2021),  
209 042004.
- 210 [13] S.L. Khan, F.A. Siddiqui, S.P. Jain and G.M. Sonwane, Discovery of potential inhibitors of SARS-CoV-2 (COVID-19)  
211 Main Protease (Mpro) from *Nigella Sativa* (black seed) by molecular docking study, *Coronaviruses* **2** (2021), 384–402.
- 212 [14] S. Daoud, S.J. Alabed and L.A. Dahabiyeh, Identification of potential COVID-19 main protease inhibitors using  
213 structure-based pharmacophore approach, molecular docking and repurposing studies, *Acta Pharmaceutica* **71** (2021),  
214 163–74.
- 215 [15] Y. Ashjaee and H. Zandi, Molecular analysis of 5-COR derivatives of uracil and evaluating their affinity against the  
216 MPro target of COVID-19, *Advanced Journal of Science and Engineering* **2** (2021), 79–85.
- 217 [16] D. Kumar, V. Chandel, S. Raj and B. Rath, In silico identification of potent FDA approved drugs against Coronavirus  
218 COVID-19 main protease: A drug repurposing approach, *Chemical Biology Letters* **7** (2020), 166–75.
- 219 [17] H. Khalid, R. Hussain and A. Hafeez, Virtual screening of piperidine based small molecules against COVID-19,  
220 *Lab-in-Silico* **1** (2020), 50–5.
- 221 [18] M. Mirzaei, K. Harismah, M. Da'i, E. Salarrezaei and Z. Roshandel, Screening efficacy of available HIV protease  
222 inhibitors on COVID-19 protease, *Journal Military Medicine* **22** (2020), 100–7.
- 223 [19] B. Shah, P. Modi and S.R. Sagar, In silico studies on therapeutic agents for COVID-19: drug repurposing approach,  
224 *Life Sciences* **252** (2020), 117652.
- 225 [20] T. Joshi, T. Joshi, P. Sharma, S. Mathpal, H. Pundir, V. Bhatt and S. Chandra, In silico screening of natural com-  
226 pounds against COVID-19 by targeting Mpro and ACE2 using molecular docking, *European Review for Medical and*  
227 *Pharmacological Sciences* **24** (2020), 4529–36.
- 228 [21] Y. Wang, M. Wu, X. Tan and J. Gu, Insights into the reaction mechanism between phosphacyclopropenylidene and  
229 methyleneimine: a theoretical study, *Main Group Chemistry* **19** (2020), 237–44.
- 230 [22] X.F. Wang, P. Gao, Y.F. Liu, H.F. Li and F. Lu, Predicting thermophilic proteins by machine learning, *Current*  
231 *Bioinformatics* **15** (2020), 493–502.
- 232 [23] Q. Zou, P. Xing, L. Wei and B. Liu, Gene2vec: gene subsequence embedding for prediction of mammalian N6-  
233 methyladenosine sites from Mrna, *RNA* **25** (2019), 205–18.
- 234 [24] Q. Xu, Y. Zeng, W. Tang, W. Peng, T. Xia, Z. Li, F. Teng, W. Li and J. Guo, Multi-task joint learning model for  
235 segmenting and classifying tongue images using a deep neural network, *IEEE Journal of Biomedical and Health*  
236 *Informatics* **24** (2020), 2481–9.
- 237 [25] R.K. Narayanasamy, P. Rada, A. Zdrha, M. van Ranst, J. Neyts and J. Tachezy, Cytidine nucleoside analog is an  
238 effective antiviral drug against *Trichomonas* virus, *Journal of Microbiology, Immunology and Infection*. 2021; in press.
- 239 [26] K.M. Rana, J. Maowa, A. Alam, S. Dey, A. Hosen, I. Hasan, Y. Fujii, Y. Ozeki and S.M. Kawsar, In silico DFT study,  
240 molecular docking, and ADMET predictions of cytidine analogs with antimicrobial and anticancer properties, *In Silico*  
241 *Pharmacology* **9** (2021), 1–24.
- 242 [27] R. Yaghoobi and M. Mirzaei, Computational analyses of cytidine and aza-cytidine molecular structures, *Lab-in-Silico*.  
243 **1** (2020), 21–6.
- 244 [28] X.K. Wong and K.Y. Yeong, From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug  
245 Candidates. *Current Medicinal Chemistry*. 2021; in press.
- 246 [29] M. Niu, Y. Lin and Q. Zou, sgRNACNN: identifying sgRNA on-target activity in four crops using ensembles of  
247 convolutional neural networks, *Plant Molecular Biology* **105** (2021), 483–95.
- 248 [30] E. Dolečelová, T. Klejch, P. Špaček, M. Slapničková, L. Guddat, D. Hocková and A. Zíková, Acyclic nucleoside phos-  
249 phonates with adenine nucleobase inhibit *Trypanosoma brucei* adenine phosphoribosyltransferase *in vitro*, *Scientific*  
250 *Reports* **11** (2021), 1–27.

- 251 [31] G.N. Chua, K.L. Wassarman, H. Sun, J.A. Alp, E.I. Jarczyk, N.J. Kuzio, M.J. Bennett, B.G. Malachowsky, M. Kruse  
252 and A.J. Kennedy, Cytosine-based TET enzyme inhibitors, *ACS Medicinal Chemistry Letters* **10** (2019), 180–5.
- 253 [32] P.A. Ghamsari, M. Samadzadeh and M. Mirzaei, Halogenated derivatives of cytidine: structural analysis and binding  
254 affinity, *Journal of Theoretical and Computational Chemistry* **19** (2020), 2050033.
- 255 [33] C. Crane, A.E. Hirsch, M. Alphey, T. Sgraja, S. Lauw, V. Illarionova, F. Rohdich, W. Eisenreich, W. Hunter, A.  
256 Bacher and F. Diederich, Synthesis and characterization of cytidine derivatives that inhibit the kinase IspE of the  
257 non-mevalonate pathway for isoprenoid biosynthesis, *ChemMedChem* **3** (2008), 91.
- 258 [34] D. Hayakawa, N. Sawada, Y. Watanabe and H. Gouda, A molecular interaction field describing nonconventional  
259 intermolecular interactions and its application to protein–ligand interaction prediction, *Journal of Molecular Graphics  
260 and Modelling* **96** (2020), 107515.
- 261 [35] B. Puffer, C. Kreutz, U. Rieder, M.O. Ebert, R. Konrat and R. Micura, 5-Fluoro pyrimidines: labels to probe DNA and  
262 RNA secondary structures by 1D 19 F NMR spectroscopy, *Nucleic Acids Research* **37** (2009), 7728–40.
- 263 [36] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, et al.  
264 Gaussian 09. Gaussian, Inc., Wallingford, CT 2009.
- 265 [37] D.S. Goodsell, C. Zardecki, L. Di Costanzo, J.M. Duarte, B.P. Hudson, I. Persikova, J. Segura, C. Shao, M. Voigt,  
266 J.D. Westbrook and J.Y. Young, RCSB Protein Data Bank: Enabling biomedical research and drug discovery, *Protein  
267 Science* **29** (2020), 52–65.
- 268 [38] N.S. Patil and S.H. Rohane, Organization of Swiss Dock: In study of computational and molecular docking study,  
269 *Asian Journal of Research in Chemistry* **14** (2021), 145–8.
- 270 [39] Y. Huang, C. Rong, R. Zhang and S. Liu, Evaluating frontier orbital energy and HOMO/LUMO gap with descriptors  
271 from density functional reactivity theory, *Journal of Molecular Modeling* **23** (2017), 1–2.
- 272 [40] M.M. Rahman, T. Saha, K.J. Islam, R.H. Suman, S. Biswas, E.U. Rahat, M.R. Hossen, R. Islam, M.N. Hossain, A.A.  
273 Mamun and M. Khan, Virtual screening, molecular dynamics and structure–activity relationship studies to identify  
274 potent approved drugs for Covid-19 treatment, *Journal of Biomolecular Structure and Dynamics* **39** (2021), 6231–41.
- 275 [41] L.R. de Souza Neto, J.T. Moreira-Filho, B.J. Neves, R.L. Maidana, A.C. Guimarães, N. Furnham, C.H. Andrade and  
276 F.P. Silva Jr., In silico strategies to support fragment-to-lead optimization in drug discovery, *Frontiers in Chemistry* **8**  
277 (2020), 93.